Research · 10 min read
What an Expiration Date on a Medication Certifies
It is the output of a written stability testing program, tied to a specific container and to the storage conditions printed on the label. Change either one and the date's basis no longer describes what you are holding.
Key takeaways
- An expiration date must be determined by stability testing, and it stands behind four named qualities: identity, strength, quality and purity at the time of use.
- The date is tied to the storage conditions printed on the labeling, so the two have to be read together.
- Stability testing must be done in the same container-closure system the product is marketed in, which makes the date a property of the package as well as the drug.
- Accelerated studies can support a tentative date only while full shelf life studies are underway, so an early dating period can later change.
- A product meant to be reconstituted must carry expiration information for both forms.
- These rules sit inside the minimum current good manufacturing practice regulations, whose statutory hook is the adulteration clause on conformity with cGMP.
- Section 503A's exemption list names that cGMP clause; section 503B's list does not.
- Beyond-use date is a different term with a different basis, and is not interchangeable with an expiration date under these rules.
Answer first: the date is an output, not an estimate
The regulation states the purpose in its first line. To assure that a drug product meets applicable standards of identity, strength, quality and purity at the time of use, it shall bear an expiration date determined by appropriate stability testing.
Four qualities, named. Identity, strength, quality, purity. That is what the date is standing behind, and it is a narrower and more specific claim than "still good".
The date is not chosen by the company as a marketing decision. It has to be determined by testing described in a separate section of the same regulation, which sets out what that testing program must contain.
One further sentence closes an assumption. Expiration dates shall be related to any storage conditions stated on the labeling, as determined by those stability studies. The date and the storage instruction are a pair, not two independent facts.
What the testing program has to include
There must be a written testing program designed to assess the stability characteristics of drug products, and the results are used to determine both appropriate storage conditions and expiration dates. The program has to be followed and has to include five things.
Sample size and test intervals based on statistical criteria for each attribute examined, to assure valid estimates of stability.
Storage conditions for the samples retained for testing.
Reliable, meaningful and specific test methods.
Testing of the drug product in the same container-closure system as the one in which it is marketed.
And testing of products meant to be reconstituted at dispensing, both before and after reconstitution.
That fourth item is the one worth pausing on. The date belongs to the product in that container, with that closure. It is not a property of the molecule floating free of its packaging.
Why some dates are provisional
An adequate number of batches of each product must be tested to determine an appropriate expiration date, and a record of the data must be kept.
Then the rule allows a shortcut, with a condition attached. Accelerated studies may be used to support tentative expiration dates, combined with basic stability information on the components, the product and the container-closure system. The proviso is that full shelf life studies are not available and are being conducted.
And where accelerated data project a tentative date beyond what actual shelf life studies support, stability studies must continue, with testing at appropriate intervals, until the tentative date is verified or the appropriate date determined.
So an early date on a newly marketed product can be a placeholder that the real-time data has not yet caught up with. A later change to a dating period is not necessarily a sign that something went wrong; it can be the study finishing.
Two dates, and where the date has to appear
Where a product is to be reconstituted at the time of dispensing, its labeling must bear expiration information for both the reconstituted and the unreconstituted product.
Those two periods are not the same length and are not answering the same question. One describes a sealed product sitting in its container. The other describes a solution after it has been made up.
Expiration dates must also appear on labeling in accordance with a separate placement regulation, which is where the rules about how the date is displayed live.
A practical consequence follows. If a product arrives with a single date and no instruction about a post-preparation period, that is a question worth asking rather than an omission to assume away.
The four exemptions
The section carves out four situations, and each says something about what dating is for.
Homeopathic drug products are exempt from the expiration dating section. They are handled under a reduced stability requirement instead. It calls for a written assessment based at least on testing or examination for compatibility of the ingredients, plus marketing experience indicating no degradation over the normal or expected period of use. That evaluation uses the same container-closure system in which the product is marketed.
Allergenic extracts labeled "No U.S. Standard of Potency" are exempt from both the dating section and the stability testing section.
New drug products for investigational use are exempt from the dating requirement, provided they meet appropriate standards or specifications as demonstrated by stability studies during their use in clinical investigations. If such a product is to be reconstituted at dispensing, its labeling must still bear expiration information for the reconstituted form.
And there is a long-standing non-enforcement position, pending consideration of a proposed exemption published in 1978. It covers human over-the-counter products whose labeling bears no dosage limitations, and which are stable for at least three years as supported by appropriate stability data.
Why this is enforceable at all
The dating and stability sections both sit inside part 211, which states its own scope directly: it contains the minimum current good manufacturing practice for preparation of drug products for administration to humans or animals.
The teeth come from the statute. A drug is deemed adulterated if the methods used in, or the facilities or controls used for, its manufacture, processing, packing or holding do not conform to current good manufacturing practice. The same applies where they are not operated or administered in conformity with it. The purpose the statute names is to assure the drug meets its safety requirements, and has the identity, strength, quality and purity characteristics it purports or is represented to possess.
Read that clause against the dating rule and the same four qualities appear in both. Identity, strength, quality, purity. The expiration date is the manufacturing standard's own promise, expressed as a date.
The statute also spells out part of what the term covers. Current good manufacturing practice includes implementing oversight and controls over the manufacture of drugs to ensure quality. That reaches managing the risk of, and establishing the safety of, raw materials, materials used in manufacturing, and finished drug products.
The compounding split, quoted rather than summarized
Two federal compounding sections open with an exemption list, and the difference between the two lists is the whole point.
Section 503A begins: sections 351(a)(2)(B), 352(f)(1), and 355 of this title shall not apply to a drug product compounded for an identified individual patient, where the conditions of the section are met.
Section 503B begins: sections 352(f)(1), 355, and 360eee–1 of this title shall not apply to a drug compounded by or under the direct supervision of a licensed pharmacist. The facility must have elected to register as an outsourcing facility, and the section's conditions must be met.
The first citation in the 503A list is the adulteration clause about conformity with current good manufacturing practice — the clause quoted in the previous section. It is present in the 503A list and absent from the 503B list.
So a traditional compounded preparation is exempt from the statutory provision that the dating and stability rules implement, while an outsourcing facility is not exempt from it. That is a difference in which federal rules attach, not a safety finding about any pharmacy.
Section 503B also puts dating on the package directly. Among the items its labeling provision requires are the date that the drug was compounded and the expiration date — two separate fields, which is a more informative pair than either alone.
One terminology note. Pharmacy practice standards use the term beyond-use date for compounded preparations, and it is assigned on a different basis from an expiration date under part 211. The two words are not interchangeable, and the material above is about expiration dating only.
How to read the date on what you were sent
Read the date and the storage line together. The regulation ties them, so a date read without its storage condition is only half the statement.
Notice the container. The testing behind the date was done in the same container-closure system the product is marketed in, so a product moved out of that container is outside what the date was measured on.
Look for a second date if anything has to be mixed, diluted or made up before use. The rule requires expiration information for both forms.
For a compounded preparation from an outsourcing facility, look for both the compounding date and the expiration date, since the statute requires both to appear.
And treat the date as the end of a supported period rather than a switch that flips. What the regulation certifies is that the product meets standards of identity, strength, quality and purity at the time of use within that period. It makes no statement about what happens on the day after.
Sources
- 21 CFR 211.137 — Expiration datingParagraph (a) for the requirement that a product bear an expiration date determined by appropriate stability testing to assure it meets applicable standards of identity, strength, quality and purity at the time of use. Paragraph (b) for the tie between expiration dates and the storage conditions stated on the labeling. Paragraph (c) for dual expiration information on products reconstituted at dispensing. Paragraph (d) for placement in accordance with 21 CFR 201.17. Paragraph (e) for the homeopathic exemption, (f) for allergenic extracts labeled "No U.S. Standard of Potency", (g) for investigational new drug products including the reconstitution proviso, and (h) for the non-enforcement position pending a proposed exemption published in the Federal Register of September 29, 1978, covering human OTC products without dosage limitations that are stable for at least three years on appropriate data.
- 21 CFR 211.166 — Stability testingParagraph (a) for the written testing program, its use in determining storage conditions and expiration dates, and its five required contents — statistically based sample size and test intervals for each attribute, storage conditions for retained samples, reliable meaningful and specific test methods, testing in the same container-closure system as marketed, and testing of reconstituted products before and after reconstitution. Paragraph (b) for the adequate-number-of-batches requirement, record retention, the use of accelerated studies to support tentative expiration dates only where full shelf life studies are not available and are being conducted, and the requirement to continue testing until a tentative date is verified or the appropriate date determined. Paragraph (c) for the reduced homeopathic stability assessment including the same container-closure requirement, and (d) for the allergenic extract exemption.
- 21 CFR 211.1 — ScopeParagraph (a), stating that the regulations in part 211 contain the minimum current good manufacturing practice for preparation of drug products for administration to humans or animals. This is the link that lets the expiration dating and stability sections be described as cGMP requirements rather than as free-standing rules.
- 21 U.S.C. 351 — Adulterated drugs and devicesSubsection (a)(2)(B), deeming a drug adulterated if the methods used in, or the facilities or controls used for, its manufacture, processing, packing or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that the drug meets the chapter's safety requirements and has the identity and strength, and meets the quality and purity characteristics, it purports or is represented to possess. Also the closing sentence defining that current good manufacturing practice includes implementing oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in manufacturing, and finished drug products.
- 21 U.S.C. 353a — Pharmacy compounding, and 21 U.S.C. 353b — Outsourcing facilitiesThe two exemption lists, read verbatim from the opening sentence of each section. Section 353a(a): "Sections 351(a)(2)(B), 352(f)(1), and 355 of this title shall not apply to a drug product if the drug product is compounded for an identified individual patient…". Section 353b(a), at https://www.govinfo.gov/content/pkg/USCODE-2023-title21/html/USCODE-2023-title21-chap9-subchapV-partA-sec353b.htm: "Sections 352(f)(1), 355, and 360eee–1 of this title shall not apply to a drug compounded by or under the direct supervision of a licensed pharmacist in a facility that elects to register as an outsourcing facility…". Also 353b(a)(10)(A)(iii), requiring the label to bear the date that the drug was compounded and the expiration date.
Frequently asked questions
What does an expiration date actually promise?
That the product meets applicable standards of identity, strength, quality and purity at the time of use, based on appropriate stability testing. Those four qualities are named in the regulation, and they are a narrower claim than a general assurance that the product is fine. The date must also be related to the storage conditions stated on the labeling, as determined by the same stability studies.
Does the date still apply if the product was stored differently?
The regulation ties the two together: expiration dates shall be related to any storage conditions stated on the labeling, as determined by stability studies. So the date is a statement about a product kept as the label directs. A product stored outside those conditions is outside what the studies measured, and the date is not answering that question.
Why do some products have two dates?
Because a product meant to be reconstituted at the time of dispensing must carry expiration information for both the reconstituted and the unreconstituted forms. The stability testing program is also required to cover both — testing of products for reconstitution as directed in the labeling, as well as after they are reconstituted. The sealed product and the made-up solution are different stability questions.
Can a dating period change after a product is on the market?
Yes, and the mechanism is written into the rule. Accelerated studies, combined with basic stability information on the components, the product and the container-closure system, may support a tentative expiration date while full shelf life studies are being conducted. Where the tentative date runs beyond what actual shelf life studies support, testing must continue at appropriate intervals until the tentative date is verified or the appropriate date determined.
Does the same rule apply to a compounded preparation?
Not in the same way, and the difference is in two exemption lists. Section 503A states that sections 351(a)(2)(B), 352(f)(1) and 355 shall not apply to a preparation compounded for an identified individual patient meeting its conditions. Section 503B states that sections 352(f)(1), 355 and 360eee–1 shall not apply to a drug compounded in a registered outsourcing facility meeting its conditions. The first of those citations is the current good manufacturing practice adulteration clause, and it appears in one list and not the other. Section 503B separately requires the label to carry both the date the drug was compounded and the expiration date.
Is a beyond-use date the same thing?
No. Beyond-use date is the term pharmacy practice standards use for compounded preparations, and it is assigned on a different basis from an expiration date determined under the manufacturing regulations described here. Treating the two as interchangeable is a common mistake, and it leads people to assume a compounded preparation's date rests on the same kind of testing program.
Are any products exempt from carrying a date?
Four categories are addressed. Homeopathic drug products are exempt from the dating section and fall under a reduced stability assessment instead. Allergenic extracts labeled "No U.S. Standard of Potency" are exempt from both the dating and stability sections. New drug products for investigational use are exempt, provided they meet appropriate standards or specifications demonstrated by stability studies during clinical investigations. And there is a long-standing non-enforcement position for certain over-the-counter products whose labeling bears no dosage limitations and which are stable for at least three years on supporting data.